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Summary
Osteopenia and osteoporosis are frequent in HIV-infected pa-
tients, because of disease itself and therapy. This study evalu-
ated the incidence of bone disorders in 18 infected pregnant
women treated with antiretroviral drugs and in their uninfect-
ed children.
Biochemical markers of bone metabolism were obtained every
three months in pregnant women and at 1, 6 and 12 month of
age in children. Serum levels of calcium, inorganic phosphate,
bone specific alkaline phosphatase were collected; moreover
serum levels of osteocalcin and urinary CTX concentrations
were evaluated as bone synthesis and bone resorption index
respectively. Ultrasonographic bone densitometry was per-
formed in women once in pregnancy and in children at 1, 6, 12
months of age. In order to critically analyze these data, a nor-
mal line was generated from data obtained from a cohort of 80
italian children aged 0-12 months: this is the first study ever
performed on newborns and infants, in the aim to identify the
normal values of reference in this cluster of age.
Lower bone density values, compared with control subjects,
were detected in 7/18 women (38.8%): osteopenia was found
in 3 women and osteoporosis in 4. Normal serum levels of os-
teocalcin were detected in osteopenic patients while the
serum concentrations were low (< 2.5 ng/ml) all over pregnan-
cy in the four cases of osteoporosis. High CTX urinary con-
centration was observed in 3 cases of osteoporosis. 
In just 2 children (born to women who had started an anti-
retroviral therapy with PIs before conception and have been
treated for more than 30 months) low bone density was diag-
nosed by ultrasonographic densitometry at the first month,
but it was found normal both at 6 and 12 months of age. Only
in these two cases high CTX urinary concentration was ob-
served at the first month, and was found normal at the follow-
ing evaluations.
The pathogenesis of low bone density observed in pregnant
women is multifactorial, involving HIV- and HAART- related
factors. Bone metabolism resulted normal in most children
perhaps because of the lack of HIV infection.
KEY WORDS: HIV, HAART, bone metabolism, bone density, pregnancy,
children.
Introduction
In both HIV-infected adults and children skeletal abnormalities, in-
cluding decreased bone mineral content and bone mineral densi-
ty are frequently reported (1-4), although the mechanisms of the
pathogenesis of these alterations have not completely assessed.
Several studies have concluded that, at least in infected adults,
bone disorders are strongly associated with HIV itself that can
infect osteoblasts or indirectly alter osteoclast and osteoblast
function through T-cell activation and increased production of
bone-resorbing cytokines like IL-1, IL-6 and TNF-alfa (5-7).
Besides, the duration of infection, often causing physical inac-
tivity and poor nutrition, can contribute to decrease bone min-
eral content and increase bone turnover in HIV-infected pa-
tients (8-11). 
On the other hand, in HAART (Highly Active Antiretroviral Ther-
apy) era many reports on bone disorders in HIV-infected adults
and all of those in children suggest that prolonged administra-
tion of protease inhibitor (PI)-containing regimens plays a role
in the pathogenesis of abnormal bone metabolism, by inducing
osteoclast and osteoblast dysfunction.
With regard to HIV-infected HAART-treated pregnant women,
the evolution of bone mineralization and metabolism has not
thoroughly studied yet.
The lack of data about the bone changes occurring over time in
these subjects and about the risk of consequences in their
newborns and infants (infected or not) who are exposed “in
utero” to the same antiretroviral drugs prompted us to study the
bone metabolism in a cohort of HIV-infected pregnant women
treated with different therapeutic protocols and in their children,
followed from birth to the end of the first year of life with bone
mineral measurements and with serial controls of biochemical
markers of bone turnover.
Patients and methods
We evaluated the incidence of bone disorders in 18 HIV-infect-
ed pregnant women aged 25-39 years (mean 30 years) and in
their 18 children (10 males, 8 females) followed from 0 to 12
months of age at the Department of Infectious Diseases in col-
laboration with the Department of Orthopaedics and Trauma-
tology, “Città di Pavia” Institute, of the University of Pavia.
The control group of pregnant women included 20 white sub-
jects of the same age, healthy and physically active; none of
them had an history of chronic illness or was regularly treated
with hormone therapy, vitamin supplement or calcium; the con-
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trol group of children included 80 Italian healthy males and fe-
males aged from 0 to 12 months.
The characteristics of the pregnant women are shown in Table I.
In 14 cases the pregnancy lasted 38 weeks and an elective
caesarean section was performed; 4 women delivered prema-
turely (after 32-36 weeks of pregnancy) by emergency cae-
sarean section. 
Biochemical markers of bone metabolism were obtained every
three months in pregnant women and at 1, 6 and 12 months of
age in children.
The following metabolic parameters were collected: serum lev-
els of calcium, inorganic phosphate, bone specific alkaline
phosphatase, serum levels of osteocalcin (evaluated as bone
synthesis index), urinary CTX (C-terminal telopeptide of type 
1-collagen) concentration (evaluated as bone resorption in-
dex).
Blood was collected by venipuncture and serum samples, sep-
arated by centrifugation, were evaluated at once. Urine sam-
ples were collected from the second voiding of the day, with
the aim of standardizing the results by reducing the effect of
circadian rhythm of CTX urinary elimination; the samples were
stored at -30°C until analysis effected by an enzyme-im-
munosorbent assay.
CTX is an eight aminoacid sequence found on the C-terminal
end of type 1-collagen. When the collagen molecules are bro-
ken down, the presence of this sequence specifically indicates
bone breakdown. The rate of bone resorption is proportional to
the urinary level of CTX. This parameter is a reliable index of
degradation and not of biosynthesis of molecules deriving from
collagen. 
In this study, urinary excretion of these breakdown products of
type 1-collagen was determined by the Osteosal (Provalis Ltd,
Deeside, UK) quantitative immunochromatographic assay,
which employes high affinity monoclonal antibodies specific for
CTX. All determinations were corrected for creatinine. 
Osteosal results are expressed as a T-score, similarly to the bone
density measurements. A population of 200 pre-menopausal
women were tested with Osteosal to assess their CTX levels; a
mean CTX value was calculated for this population and was in-
dicated as T-score of 0. The standard deviation was also cal-
culated and this value was indicated as T-score of 1. Osteosal
T-scores are defined as the number of standard deviations
from the mean of a normal pre-menopausal population (12).
A positive or negative T-score is equivalent to a higher or lower
rate of bone turnover. It is to be emphasized that the bone den-
sity T-score increases as bone density increases, while the Os-
teosal T-score decreases as the rate of bone turnover decreas-
es.
Bone mineral density (BMD) was measured by ultrasonograph-
ic densitometry with an Omnisense device (Sunlight Technolo-
gies, Rehovot, Israel), performed once in pregnancy in women
and at 1-6-12 months of age in children. This device measures
non-invasively the velocity of ultrasound waves (speed of
sound, SOS, in m/sec) propagating along the bone.
The ultrasonographic densitometry has been chosen as diag-
nostic method because of its high sensitivity and its safety, al-
lowing to use it even more than once in pregnant women, in
newborns and infants. Moreover, Omnisense device allows to
perform a “multisite” bone density measurement that result in a
more accurate diagnosis. In addition, Omnisense is a small,
lightweight and easy to handle device, and their results are im-
mediately available. 
In women measurements were performed at proximal phalanx
of the medium finger, at tibia and at distal radius, while in new-
borns and infants tibia site only was considered, due to the
bone size. According to the criteria established by the WHO for
the diagnosis of osteoporosis, in this study patients with a T-
score between +1 and –1 SD from the mean of healthy young
adults were considered as normal, patients with a T-score be-
tween –1 and –2,5 SD were consideres as osteopenic, patients
with a T-score under –2,5 SD were considered as osteoporotic.
In order to critically interpret the sonographic results of the chil-
dren included in our study, we have for the first time drawn a
diagram of reference with the data obtained by the same de-
vice in the control group. 
Speed of sound values, indicatory of bone density, obtained
in children born to HIV-infected women, were compared with
those obtained by means of the same device in a control
group of 80 italian healthy newborns and infants aged 0-12
months.
A detailed reference curve for this age interval is not provided
by the Omnisense device: only a “general” pediatric reference
curve from 0 to 21 years is provided, without making any dis-
tinction in months inside the first year of age. Therefore, an
Italian diagram of reference for this age, based on the values
obtained in the control group, was drawn for the first time. 
The availability of this diagram (taking into account the eating
habits of Italian newborns and infants) allowed us to make an
accurate diagnosis of bone density alterations in children in-
cluded in this cluster of age. We could use the diagram of ref-
erence also for black children, because their mothers had lived
in our country for years and were keeping the alimentary habits
of italian people. Two diagrams (for males and females) were
obtained. In each diagram 3 lines are shown: the central line
indicates the means of the measured SOS values in the control
group, while the dotted lines show the standard deviations (+1
and –1 SD respectively). 
The female diagram shows a tendency to increase until the 3rd
month, followed by a decrease with a minimum peak at the 4th
month, a definite increase of the values until the 6th month and
a further increase from the 6th month on. The male diagram is
quite different, with a decrease of the values from the birth to
the 4th month and a progressive increase in the following peri-
od.
Values obtained from children born to HIV-infected women,
Table I - Characteristics of 18 HIV-infected pregnant women.
Age 26-39 years
Race White 12
African 5
South-American 1
Clinical stage Asymptomatic 17
AIDS 1*
CD4+ cells/mm3 (medium level) > 500 3
> 200 < 500 14
< 200    1
Antiretroviral therapy during pregnancy** ZDV or ZDV/3TC 5
NRTIs (2) + PI (1 or 2) 7
NRTIs (2) + NVP 6
* AIDS was diagnosed three years before the pregnancy, because of Pneu-
mocystis carinii pneumonia and CMV disseminated infection.
** 7/18 women had started the antiretroviral therapy before the conception
and kept on taking the same drugs during pregnancy; the others started the
therapy from the second trimester of pregnancy.
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placed above the lower dotted line were considered as normal;
values placed below this line were considered as index of os-
teopenia (Fig. 1 A,B).
With regard to HIV infection follow-up in pregnant women,
CD4+ lymphocytes and HIV viral load (HIV-RNA) were monthly
evaluated.
Infants were said to be HIV uninfected either if two negative
test results (by PCR or bDNA test) were available with the lat-
est being at 2 months of age or later or if one or more negative
test results were available at 3 months of age or later. 
Results
Both in pregnant women and in children the serum levels of
calcium, inorganic phosphate and bone specific alkaline phos-
phatase were always normal.
By ultrasonographic densitometry lower bone density values,
compared with control subjects, were detected in 7/18 women
(38.8%).
Osteopenia was found in 3 women and osteoporosis in 4: nor-
mal serum levels of osteocalcin were detected in osteopenic
patients while the serum concentrations were low (< 2.5 ng/ml)
all over pregnancy in the four cases of osteoporosis.
High CTX urinary concentration (more than +2 SD higher T-
score) was observed in 3 cases of osteoporosis. 
With regard to antiretroviral therapy, 6/7 women with low BMD
have been treated  for at least two years before the conception
with different HAART protocols including the following PIs: Nel-
finavir (NFV) (3 cases), Indinavir (IDV) (1 case), Lopinavir/Ri-
tonavir (LPV/RTV) (2 cases).
No relation was observed between BMD alterations and de-
gree of immunodepletion.
In 11/18 pregnant women BMD resulted constantly normal,
with normal serum levels of osteocalcin and CTX urinary con-
centration in 8 of them. 
These patients had started antiretroviral therapy during preg-
nancy: 4 were treated with PIs while the others were just re-
ceiving two NRTIs either combined or not with NVP.
In all children the results of biochemical measurements per-
formed on blood and urine samples during the first year of life
to evaluate the bone turnover were similar to those of healthy
subjects.  
In the 11 children born to mothers with normal bone mass dur-
ing pregnancy, the ultrasonographic data, evaluated in com-
parison with the diagram of reference, resulted normal all over
the first year of life.
In just 2 of the 7 remaining children (born to women who had
started an antiretroviral therapy with PIs before conception and
have been treated for more than 30 months) osteopenia and,
respectively, osteoporosis were diagnosed by ultrasonographic
densitometry at the first month of life, but their bone density
was found normal both at 6 and 12 months of age. 
Only in these two cases high CTX urinary concentration (more
than +1,5 and +2 SD higher T-score respectively) was ob-
served at the first month of life; this parameter was found nor-
mal at the following evaluations.
No cases of vertically transmitted HIV infection were detected.
Discussion
Although there is evidence for bone metabolism alterations in
adult and young patients treated with HAART, data are still
lacking with regard to HIV-infected pregnant women, who more
and more frequently receive antiretroviral drugs not only to re-
duce the HIV vertical transmission rate but also to improve the
virological and immunological parameters of infection (9, 13,
14).
The incidence of osteopenia and osteoporosis in healthy preg-
nant women is unclear, because many other elements (such
as increase in weight, smoke, alcohol, physical activity), in ad-
dition to pregnancy, can influence the bone mass in this period.
Longitudinal studies demonstrated that, during pregnancy and
breast feeding, a loss of bone mass > 5% can occur, but this
loss is reversible (15, 16).
In our cohort of pregnant women the ultrasonographic densito-
metry proved to be the most effective test for an early diagno-
sis of bone turnover alterations: by means of this technique we
were able to demonstrate osteopenia and osteoporosis in a
high number of cases in spite of normal serum indexes of bone
formation and resorption like calcium, inorganic phosphate and
bone specific alkaline phosphatase. Besides, our data show
that just in a few cases serum level of osteocalcin and CTX uri-
nary concentration can be considered like sensitive markers of
increased bone synthesis or bone resorption. 
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Figure 1 A, B - Male and female diagrams showing the means of the measured SOS values in the control group (central continuous line) with +1 and
–1 SD (dotted lines), and values obtained from children born to HIV-infected women (circles).
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The high incidence of osteopenia and osteoporosis found in
the women of our cohort seems to be associated with the role
of PIs (particularly of NFV, IDV and RTV) in the pathogenesis
of bone loss frequently described in HIV-infected adults (1, 17).  
We can moreover speculate that the duration of PIs adminis-
tration can also have effect on the bone metabolism not only in
women but also in newborns exposed “in utero” to the same
drugs, because in our cases we observed that a higher rate of
low bone mass in pregnancy corresponded to a longer duration
of PIs administration (at least 24 months) and that the longest
duration of maternal treatment (> 30 months) was related to a
higher risk of osteopenia and osteoporosis in newborns.
We could rightly interpret the results of ultrasonographic den-
sitometry in the followed newborns and infants because for the
first time we were able to use the diagram of reference drawn
by us on the basis of the results obtained among the control
group of paediatric patients aged from 0 to 12 months.
By this way osteopenia and osteoporosis respectively were diag-
nosed at birth in two infants; nevertheless bone mass resulted
normal in both of them at 6 and 12 months of age, most likely be-
cause the lack of HIV-infection strongly protected them against
prolonged side effects of maternal antiretroviral therapies.
To confirm this hypothesis, prospective studies about higher
number of children both HIV-infected and uninfected born to
women treated with highly active combination of antiretroviral
drugs during pregnancy are needed to definitely establish the
effects of vertically acquired infection and of perinatal exposure
to antiretroviral drugs on bone metabolic rate.
As more and more cases of osteonecrosis and fractures among
patients receiving antiretroviral drugs are being reported, it is
important to assess therapeutic protocols and management
programs to minimize from childhood and adolescence the
risks of skeletal deformities and pathological fractures and to
protect also HIV-infected pregnant women against this meta-
bolic complication of both infection and therapy (1, 18-21).  
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